



## Changing dynamics pressuring AlHammadi in short run with risks on patient attraction and cost; we revise our TP down to SAR 52.0 per share

AlHammadi, in Q2-24, posted its third consecutive set of quarterly results displaying negative Y/Y top line growth, reaching SAR 263.5mn (down 4.8% Y/Y and 4.9% Q/Q), while recording a bottom line of SAR 117.9mn (up 44.0% and 84.1% Q/Q) supported by a non-recurring income of SAR 55.3mn from the sale of its Al Riyan land. One off aside, AlHammadi would have posted a 23.5% decrease in NI Y/Y. Its pressures are seen at the top line due to the seasonality at play, as well as the effect its pricing strategy had on its insurance customers, which management expects to gradually normalize by the end of the year. Furthermore, its GP margin, reaching 32.5% (down 80bps Y/Y and 40bps Q/Q) reflected the ongoing changes at AlHammadi, which management expects to carry on for the remainder of the year as it faces changes in MoH agreements as well as investments into new services and hirings. Its targeted price hikes, and expansion campaign to increase its available capacity by c. 70% through its Olaya and Narjis expansions (400 rooms) drive our long term performance estimates for the stock; summarized by an FY23-28E revenue CAGR of 9.8% and a NI CAGR of 6.0% for the same period. At current valuations, we maintain our recommendation at "Neutral" while revising down our TP to **SAR 52.0 per share**.

**Q4-24 results displayed a continued change in the dynamics at AlHammadi, summarized by 6.0% Y/Y revenue decline in H1-24 and a 4.4 pcp GPM retraction Y/Y during the same period:** AlHammadi recorded a bottom line of SAR 117.9mn during Q2-24 (up 44.0% Y/Y, and 81.1% Q/Q); the result however was supported by a non-recurring gain of SAR 55.3mn from the sale of its plot of land in Al Riyan district. One-off aside, the firm would have recorded a 23.5% decrease in net income Y/Y (and down 2.2% Q/Q). Revenues declined 4.8% Y/Y due to declines in patient volumes during the seasonally burdened Q2, as well as lackluster performance from the pharmaceutical segment which declined 21.0% Y/Y and 6.4% Q/Q. GP margins continued to contract, reaching 32.5% (down 80bps Y/Y, and 40bps Q/Q), as Hammadi invests in new services and amid an operational capacity increases in their Suwaidi branch. Furthermore, SG&A to revenues increased by 30bps Y/Y while declining 70bps Q/Q. Operating income, however was supported by a minor impairment reversal of SAR 2mn.

**Recovery in patient volumes depend on demand on new prices amid growing competition and new insurance classification to A+/VIP. GP pressures expected to be in play till next year:** AlHammadi's H1-24 revenues were weighed down by declines in patient volumes on both the inpatient and outpatient fronts. The decline was partially due to AlHammadi being classified upwardly at the 'A+/VIP' insurance segment by insurers due to Hammadi increasing its prices as a part of its first phase of its strategy. AlHammadi intends to increase its prices further during FY24-27, with a targeted 10%-12% Y/Y price increase on insurance patients for FY25E. While patient volumes are likely to improve in the seasonably favorable H2-24, we see there lies a risk on patient volumes in AlHammadi's pricing focused strategy as insurance clients adjust to new prices, amid the increasing competition in Riyadh, and as they are now classified by insurance patients as other premium providers. Pricing initiatives favorably drive our short term forecasts on revenue growth, while the two-facility expansions extend our longer term estimates to a FY23-28 ECAGR of 9.8%. GP margins are also under pressure in the imitate term as new agreements with the MoH have MoH patients access more services at no additional compensation to AlHammadi. Adding onto the GP margin pressures are investments into new services, and hiring, which Hammadi expects the effect of to linger on till the end of the year. We expect margins to end the year at 32.0% (down 480bps Y/Y), and remaining at similar levels till FY28 while it undergoes its scheduled expansions. Our forecasts translate to a FY23-28 NI CAGR of 6.0%.

**400 room expansions on the horizon extends Hammadi's foothold in the central region:** AlHammadi's expansion campaign seeks to revive its Olaya facility (200 rooms) expected to be completed H2-26; while also on the longer term, kicking off its Narjis expansion (200 rooms) by FY28. These long term drivers will be preceded by a gradual increase in operational capacity at the Suwaidi facility (120 beds & 20 clinics). All-in-all, we estimate that AlHammadi seeks to expand its available capacity by c. 70% by FY28's end. We see that the significant expansions, at Hammadi's scale, to come at the cost of its GP margins as it dips 530bps by FY28E from FY23, while increasing its SG&A's by an estimated 77% throughout the same period.

**AJC view and valuation:** We see the changing dynamics at AlHammadi to weigh down on its bottom line for the near periods as it wrestles with sluggish patient volumes and GP margin pressures expected to carry onto for quarters to come. A nearly 70% capacity expansion drives our long term estimates to punctuate at an FY23-28E Revenue and NI CAGR of 9.8% & 6.0%, respectively. We expect Hammadi's D/E profile to remain stable in the long run as we expect its future CAPEX obligations (est at c. 1.bn till FY28E) to be able to be financed via its operating cashflow generation which amounted to 120% of net income in FY23. Notably, however, the stock could benefit from the potential listing of one of its subsidiaries, Sudair Pharma, which is expanding its operations into insulin production and respiratory medicine, and is 35% owned by AlHammadi. Potential upside risks to the valuation are present from a quicker than expected recovery in margins, or patient volumes present further upside risks to the stock. Similarly, downside risk stem from longer than expected continuation of volume setbacks in the near term as a result of pricing, more significant margin declines, as well as achieving a lower-than-intended price hike. We value the stock at 50% DCF (WACC=9.2 and terminal growth rate = 2.5%) and 50% PE (28x at FY25E earnings) to revise down our TP to **SAR 52.0 per share**, at a "Neutral" recommendation.

Recommendation	Neutral
Target Price (SAR)	52.0
Upside / (Downside)*	13.3%

Source: Tadawul \*prices as of 2<sup>nd</sup> September 2024

### Key Financials

in SAR mn, (unless specified)	FY22	FY23	FY24E	FY25E
Revenues	1,122	1,177	1,151	1,267
Growth %	17.9%	4.8%	-2.2%	10.1%
Net Income	257.3	303.3	300.1	287.7
Growth %	160.3%	17.9%	-1.1%	-4.1%
EPS	1.61	1.90	1.88	1.80
DPS	1.25	1.40	1.30	1.20

Source: Company reports, Aljazira Capital

### Key Ratios

	FY22	FY23	FY24E	FY25E
Gross Margin	37.1%	36.8%	32.0%	32.7%
OP Margin	26.0%	29.1%	29.6%	25.5%
Net Margin	22.9%	25.8%	26.1%	22.7%
EBITDA Margin	35.6%	37.4%	42.6%	39.3%
RoE	15.3%	17.1%	15.9%	14.5%
P/E (x)	24.9	31.3	24.5	25.5
P/B (x)	3.8	5.2	3.8	3.6
EV/EBITDA (x)	18.3	16.4	14.8	14.9
Dividend Yield	3.1%	2.4%	2.9%	2.7%


Source: Company reports, Aljazira Capital

### Key Market Data

Market Cap (SAR bn)	7.3
YTD%	-22.6%
52 weeks (High)/(Low)	71.8/41.4
Share Outstanding (mn)	160.0

Source: Company reports, Aljazira Capital

### Price Performance



Source: Tadawul, Aljazira Capital

Equity Analyst

Ibrahim Elaiwat

+966 11 2256115

i.elaiwat@Aljaziracapital.com.sa




**Key Financials**

Amount in SAR mn, unless otherwise specified	FY21	FY22	FY23	FY24E	FY25E	FY26E	FY27E	FY28E
<b>Income statement</b>								
Revenues	952	1,122	1,177	1,151	1,267	1,437	1,576	1,875
Y/Y	24.6%	17.9%	4.8%	-2.2%	10.1%	13.4%	9.7%	18.9%
Cost	(587.8)	(706.4)	(743.6)	(782.7)	(853.5)	(982.2)	(1,072.4)	(1,284.1)
Gross profit	364.0	416.0	433.1	368.5	413.9	454.7	503.6	590.5
Operating Expenses	(238.8)	(153.2)	(116.9)	(114.8)	(123.6)	(151.5)	(161.6)	(192.3)
SG&A Expenses	(84.3)	(98.9)	(97.9)	(100.7)	(110.9)	(137.1)	(145.9)	(173.6)
Impairment losses on trade receivable	(154.5)	(54.3)	(19.0)	(14.1)	(12.7)	(14.4)	(15.8)	(18.7)
Other operating Income/(expense)	6.0	29.0	29.4	32.2	33.4	34.4	35.9	37.2
Gain/loss from disposal of property				55.3				
Operating profit	131.2	291.8	345.6	341.1	323.6	337.7	377.9	435.4
Y/Y	20.1%	122.3%	18.5%	-1.3%	-5.1%	4.3%	11.9%	15.2%
Financing Expense	(15.7)	(21.7)	(25.8)	(24.6)	(23.5)	(20.8)	(15.5)	(10.3)
Income before zakat	117.6	274.2	321.0	317.1	302.3	319.1	364.6	427.5
Zakat	(18.7)	(16.8)	(17.6)	(17.0)	(14.6)	(15.5)	(17.7)	(20.7)
Net income	90.1	257.3	303.3	300.1	287.7	303.7	347.0	406.7
Y/Y	-31.1%	185.7%	17.9%	-1.1%	-4.1%	5.5%	14.3%	17.2%
EPS (SAR)	0.62	1.61	1.90	1.88	1.80	1.90	2.17	2.54
DPS (SAR)	0.83	1.25	1.40	1.30	1.20	1.30	1.40	1.45
<b>Balance sheet</b>								
<b>Assets</b>								
Cash & equivalent	121	61	125	276	176	133	82	341
Other current assets	442	559	649	567	589	631	650	724
Non-current assets	1,711	1,895	1,936	2,007	2,240	2,366	2,401	2,276
Property plant & equipment	1,535	1,470	1,533	1,623	1,856	1,984	2,025	1,905
Other non-current assets	164	289	277	268	268	267	264	262
Total assets	2,262	2,379	2,585	2,734	2,889	3,015	3,022	3,232
<b>Liabilities &amp; owners' equity</b>								
Total current liabilities	227	260	284	299	339	365	333	380
Long-term loans	179	203	164	174	199	199	129	99
Total other non-current liabilities	196	308	302	326	328	337	341	360
Paid -up capital	1,200	1,600	1,600	1,600	1,600	1,600	1,600	1,600
Statutory reserves	73	37	67	97	126	156	191	232
Retained earnings	386	74	178	238	297	357	427	560
Total owners' equity	1,659	1,711	1,845	1,935	2,023	2,114	2,219	2,392
Total equity & liabilities	2,262	2,482	2,594	2,734	2,889	3,015	3,022	3,231
<b>Cashflow statement</b>								
Operating activities	435	253	351	554	469	511	576	635
Investing activities	(133)	(113)	(55)	(220)	(408)	(334)	(256)	(107)
Financing activities	(194)	(201)	(232)	(183)	(160)	(221)	(371)	(269)
Change in cash	107	(60)	65	151	(100)	(43)	(51)	259
Ending cash balance	121	61	125	276	176	133	82	341
<b>Key fundamental ratios</b>								
<b>Liquidity ratios</b>								
Current ratio (x)	2.5	2.4	2.8	2.8	2.3	2.1	2.2	2.8
Quick ratio (x)	2.2	2.2	2.6	2.6	2.1	1.9	2.0	2.6
<b>Profitability ratios</b>								
Gross profit margin	38.2%	37.1%	36.8%	32.0%	32.7%	31.6%	32.0%	31.5%
Operating margin	13.8%	26.0%	29.4%	29.6%	25.5%	23.5%	24.0%	23.2%
EBITDA margin	26.2%	35.6%	37.4%	42.6%	39.3%	38.0%	38.0%	35.6%
Net profit margin	9.5%	22.9%	25.8%	26.1%	22.7%	21.1%	22.0%	21.7%
Return on assets	3.8%	10.8%	12.0%	11.3%	10.2%	10.3%	11.5%	13.0%
Return on equity	5.4%	15.3%	17.1%	15.9%	14.5%	14.7%	16.0%	17.6%
<b>Leverage ratio</b>								
Debt / equity (x)	0.13	0.14	0.10	0.11	0.12	0.12	0.06	0.04
<b>Market/valuation ratios</b>								
EV/sales (x)	5.2	5.9	8.1	6.3	5.9	5.2	4.7	3.8
EV/EBITDA (x)	19.7	16.5	21.8	14.8	14.9	13.7	12.3	10.6
EPS (SAR)	0.6	1.6	1.9	1.9	1.8	1.9	2.2	2.5
BVPS (SAR) - Adjusted	13.8	10.7	11.5	12.1	12.6	13.2	13.9	15.0
Market price (SAR)	30.23	40.10	59.40	45.90	45.90	45.90	45.90	45.90
Market-Cap (SAR mn)	4,836.0	6,416.0	9,504.0	7,344.0	7,344.0	7,344.0	7,344.0	7,344.0
Dividend yield	2.7%	3.1%	2.4%	2.9%	2.7%	2.9%	3.3%	3.2%
P/E ratio (x)	48.9	24.9	31.3	24.5	25.5	24.2	21.2	18.1
P/BV ratio (x)	2.2	3.8	5.2	3.8	3.6	3.5	3.3	3.1

Sources: AlJazira Capital, Company Financials





RESEARCH DIVISION

Head of Sell-Side Research - AGM  
Jassim Al-Jubran  
+966 11 2256248  
j.aljabran@aljaziracapital.com.sa

RESEARCH  
DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING  
TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

## Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068